BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Stock News

USA - Nasdaq - NASDAQ:BBOT - US1079241022 - Common Stock

13.14 USD

-0.55 (-4.02%)

Last: 12/8/2025, 4:30:02 PM

13.14 USD

0 (0%)

After Hours: 12/8/2025, 4:30:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BBOT Latest News, Press Relases and Analysis

All

Press Releases

20 days ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT to Participate in Upcoming December Investor Healthcare Conferences

20 days ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT to Participate in Upcoming December Investor Healthcare Conferences

a month ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

a month ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

4 months ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT to Participate in Upcoming September Investor Healthcare Conferences

a month ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT to Participate in the Jefferies Global Healthcare Conference in London

a month ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT to Participate in the Jefferies Global Healthcare Conference in London

a month ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

a month ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

a month ago - By: TheRas, Inc. (d/b/a BBOT)

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing

a month ago - By: TheRas, Inc. (d/b/a BBOT)

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing

2 months ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2 months ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2 months ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

4 months ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT to Participate in Upcoming September Investor Healthcare Conferences

4 months ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

4 months ago - By: TheRas, Inc. (d/b/a BBOT)

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition